These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2192959)

  • 21. Decapeptyl in the treatment of metastatic prostatic cancer. Comparative study with pulpectomy.
    Botto H; Richard F; Mathieu F; Camey M
    Prog Clin Biol Res; 1987; 243A():199-206. PubMed ID: 2958850
    [No Abstract]   [Full Text] [Related]  

  • 22. [New hormonal treatments of metastatic prostatic cancer. Review of the literature].
    Dubost JJ; Sauvezie B; Ristori JM; Thevenet JP; Rampon S
    Rev Rhum Mal Osteoartic; 1985 Oct; 52(10):577-85. PubMed ID: 3909364
    [No Abstract]   [Full Text] [Related]  

  • 23. Gonadotropin-releasing hormone agonists. Current uses for these increasingly important drugs.
    Winkel CA
    Postgrad Med; 1994 May; 95(6):111-8. PubMed ID: 8170869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised, double-blind study of estramustine phosphate and leuprolide acetate.
    De la Grange AB
    Prog Clin Biol Res; 1987; 243B():227-8. PubMed ID: 3116555
    [No Abstract]   [Full Text] [Related]  

  • 25. Uncommon course of carcinoma of the prostate after radical prostatectomy and luteinizing hormone-releasing hormone analogue therapy.
    Pauer W; Eckerstorfer GM
    J Urol; 1998 Oct; 160(4):1432-3. PubMed ID: 9751377
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LHRH ethylamide against prostatic cancer].
    Yamanaka H; Makino T; Kumasaka F; Shida K
    Hinyokika Kiyo; 1984 Apr; 30(4):545-60. PubMed ID: 6435416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gonadotrophin releasing hormone analogues for advanced prostate cancer.
    Drug Ther Bull; 1992 Aug; 30(17):65-7. PubMed ID: 1396111
    [No Abstract]   [Full Text] [Related]  

  • 28. [Use of LHRH agonists in the therapy of advanced cancer of the prostate].
    Fretin J
    Arch Esp Urol; 1989; 42 Suppl 2():209-11. PubMed ID: 2700882
    [No Abstract]   [Full Text] [Related]  

  • 29. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
    Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
    [No Abstract]   [Full Text] [Related]  

  • 30. Reversibility of androgen deprivation therapy in patients with prostate cancer.
    Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
    J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LHRH analogues in the treatment of prostatic cancer. Introduction.
    Dufour B
    Br J Clin Pract Suppl; 1985 Mar; 37():2-3, 14-5. PubMed ID: 3931663
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New prostate cancer drugs: few CV effects?
    Henahan J
    JAMA; 1983 Oct; 250(16):2097-9. PubMed ID: 6413706
    [No Abstract]   [Full Text] [Related]  

  • 34. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 35. [Does the pharmacological class effect between the different luteinizing hormone releasing hormone analogues used in the treatment of prostate cancer have to be assumed?].
    Vilar-González S; Maldonado-Pijuan X; Andrés-García I
    Actas Urol Esp; 2010 Oct; 34(9):749-57. PubMed ID: 20843451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The treatment of prostatic cancer by LH-RH agonist.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetsu I
    Prog Clin Biol Res; 1987; 243A():429-34. PubMed ID: 3116552
    [No Abstract]   [Full Text] [Related]  

  • 37. [Hormonal manipulation of disseminated prostatic cancer].
    Mahler C; Chaban M; Robinson M; Denis L
    Acta Urol Belg; 1984; 52(4):593-9. PubMed ID: 6097106
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
    Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
    Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers.
    Redding TW; Schally AV
    Prog Clin Biol Res; 1988; 262():217-40. PubMed ID: 2897695
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of advanced cancer of the prostate.
    Orovan WL
    Can J Surg; 1989 Sep; 32(5):315-6. PubMed ID: 2670160
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.